Immunocore (NASDAQ:IMCR) Sets New 12-Month Low - Here's Why

Immunocore logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Immunocore shares hit a new 52-week low, falling 3.7% to an intraday low of $27.31.
  • The company’s latest quarterly results missed expectations: loss per share was $0.28 versus a $0.17 forecast, while revenue of $102.22 million fell short of the $152.09 million estimate.
  • Analyst views remain mixed, though MarketBeat reports a “Moderate Buy” consensus and an average price target of $52.86.
  • Five stocks to consider instead of Immunocore.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $27.31 and last traded at $27.74, with a volume of 259,620 shares traded. The stock had previously closed at $28.88.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Immunocore in a report on Thursday, October 15th. HC Wainwright decreased their price target on Immunocore from $100.00 to $80.00 and set a "buy" rating for the company in a report on Tuesday, November 10th. TD Cowen raised Immunocore to a "strong-buy" rating in a research report on Monday, August 24th. Wall Street Zen cut Immunocore from a "buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, Zacks Research cut Immunocore from a "hold" rating to a "strong sell" rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $52.86.

View Our Latest Report on IMCR

Immunocore Trading Down 3.7%

The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -42.78 and a beta of 0.82. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.62. The business has a fifty day moving average of $30.92 and a two-hundred day moving average of $31.61.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The firm had revenue of $102.22 million for the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. As a group, equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.20 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Braidwell LP acquired a new stake in Immunocore in the 2nd quarter worth about $16,552,000. Janus Henderson Group PLC grew its holdings in Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company's stock valued at $17,919,000 after buying an additional 140,308 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Immunocore in the 2nd quarter valued at about $2,145,000. Stempoint Capital LP acquired a new position in shares of Immunocore during the 1st quarter valued at about $1,916,000. Finally, Engineers Gate Manager LP increased its stake in shares of Immunocore by 334.3% during the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company's stock valued at $1,915,000 after acquiring an additional 46,435 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body's T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company's marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunocore Right Now?

Before you consider Immunocore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.

While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines